Company Overview and News
AUSTIN, Texas, Aug. 22, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Golden Developing Solutions, Inc. (OTCMKTS: DVLP) (“DVLP” or the “Company”), an emerging leader in the CBD Products marketplace, issues the following letter to Shareholders from the CEO:
DVLP ETM.WI ETM
Chicago, IL – August 17, 2018 - Stocks in this week’s article are Entercom Communications Corp. (ETM - Free Report) , Insulet Corp. (PODD - Free Report) , ESCO Technologies Inc. (ESE - Free Report) and Tristate Capital Holdings, Inc. (TSC - Free Report) .
HD ESE ETM.WI PODD FCCTO BGSF ETM FCCTP FCCO HEAR OXY FIVE TSC FCCT
Take a company’s revenues over a given period of time, subtract the cost of production and you will have its earnings! Right from the top brass to research analysts, earnings growth interests every single one. This is because upbeat earnings serve as an indicator of a company’s profitability. It also more often than not leads to an uptick in the share price.
ESE ETM.WI PODD TSC ETM
Meredith Corporation (MDP - Free Report) reported an earnings miss in fourth-quarter fiscal 2018 after four straight quarters of beat. The bottom line declined year over year as well. However, the company’s top line came almost in line with the consensus estimate after a miss in the previous quarter. Following the dismal bottom-line performance, shares of the company have lost 6.7% on Aug 10. In addition, management issued guidance for fiscal 2019, which fell shy of analysts’ expectations.
FOX SSP EVC MDPEB ETM.WI LMHA MDP TIME LMHB FOXA ETM LM
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
2018-08-08 seekingalpha - 1
Good morning, and welcome to Entercom's Second Quarter 2018 Earnings Release Conference call. [Operator Instructions]. This conference is being recorded.
CBS CBS.A ETM.WI NYTAB CPV CBS.WD ETM
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ETM
Charter Communications Inc. (CHTR - Free Report) reported second-quarter 2018 adjusted earnings of $1.15 per share that beat the Zacks Consensus Estimate by 20 cents and surged 121.2% from the year-ago quarter. Revenues increased 4.8% year over year to $10.85 billion that beat the Zacks Consensus Estimate of $10.84 billion. Segment Details Residential revenues (79.8% of revenues) came in at $8.66 billion, up 4.
CHTR AMCX CMCSA ETM.WI TWC ETM
Chicago, IL – July 31, 2018 – Today, Zacks Equity Research discusses Broadcast Radio & TV, including AMC Networks, Inc (AMCX - Free Report) , Entercom Communications Corp (ETM - Free Report) , Sky Plc (SKYAY - Free Report) and Entravision Communications Corp (EVC - Free Report) .
EVC ALGN AMCX ETM.WI ETM
2018-07-31 zacks - 1
The Zacks Broadcast Radio and Television industry is primarily benefiting from higher spending on video advertising. Moreover, rate increases are driving distribution of revenues for industry participants. Television ad spending is also strong primarily due to higher political spending in the first-half of 2018. As a series of contests are scheduled for November, the momentum in political spending is expected to remain strong.
EVC ALGN AMCX ETM.WI ETM
Chicago, IL – July 16, 2018 – Zacks Equity Research highlights Funko (FNKO - Free Report) as the Bull of the Day and GTT Communications (GTT - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Netflix, Inc. (NFLX - Free Report) , Microsoft Corp. (MSFT - Free Report) and Skyworks Solutions, Inc. (SWKS - Free Report) .
RM AMC NFLX ETM.WI FITBI ETM SWKS MTCH ROSEU GTT FNKO MSFT FITB PAA NMM ROSE
2018-07-16 zacks - 1
Chicago, IL – July 16, 2018 – Zacks.com releases the list of companies likely to issue earnings surprises. This week’s list includes Wells Fargo (WFC - Free Report) , JPMorgan (JPM - Free Report) , Bank of America (BAC - Free Report) , Goldman Sachs (GS - Free Report) and Morgan Stanley (MS - Free Report) .
WFCNP RM FITBI ETM BAC MTCH ROSEU MS PAA NMM ROSE WFC BAC AMC ETM.WI GTT FITB
Chicago, IL – July 16, 2018 – Today, Zacks Equity Research discusses Outsourcing, including Waters Corporation (WAT - Free Report) , Mettler-Toledo International (MTD - Free Report) and PerkinElmer (PKI - Free Report) .
RM WSBF AMC WSCC ETM.WI FITBI ETM MTCH ROSEU GTT WAT FITB PAA PKI NMM ROSE
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to ETM / Entercom Communications Corp. on message board site Silicon Investor.
as of ET